Seattle-based Tasso, which makes units for the self-collection of blood samples, has landed $100 million in funding.
Tasso’s units work on the higher arm, drawing blood from a community of capillaries below the pores and skin with the push of a button. Individuals don’t want coaching to gather their very own blood, taking healthcare suppliers out of the loop and enabling purposes resembling distant affected person monitoring.
The startup’s units can accumulate liquid or dried samples that may be shipped by the mail. The Tasso OnDemand system, which collects dried samples as dots on a strip, acquired clearance this Could within the European Union for non-diagnostic makes use of, such monitoring of sufferers in scientific trials.
“Immediately, Tasso units are efficiently supporting decentralized scientific trials, scientific analysis, and distant affected person well being monitoring,” mentioned Ben Casavant, CEO and co-founder of Tasso, in a press release. Tasso additionally in October introduced a partnership with InnoVero, which makes pattern assortment kits to check for doping in athletes, utilizing dried blood spots.
Casavant co-founded the corporate with fellow bioengineer and CTO Erwin Berthier in 2011. The corporate in its early days acquired grant funding from the Protection Superior Analysis Tasks Company (DARPA), the Protection Menace Discount Company (DTRA) and the Nationwide Institute of Well being (NIH).
The brand new Collection B spherical brings the corporate’s complete funding to this point to $131 million. On prime of greater than $13 million in grants, the corporate beforehand raised $17 million in July 2020. The corporate is also buoyed by elevated curiosity in telehealth and at-home well being care.
“With the COVID-19 pandemic, there was a elementary shift in how we take into consideration healthcare, and demand for patient-centric, in-home options is bigger than ever,” mentioned Casavant.
In September, researchers on the College of Washington and Fred Hutchinson Most cancers Analysis Middle reported outcomes from a research of the Tasso-SST system to gather liquid blood. Samples self-collected by COVID-19 sufferers maintained antibody high quality much like that from samples collected and analyzed on website by a phlebotomist, even after being held for a number of days to imitate transport instances.
The system for liquid blood is designed to gather extra blood than the typical finger prick — yielding on common a few 1/3 milliliters within the research.
“We imagine that the FDA will acknowledge the scientific diagnostic worth of those exams and open pathways for authorization,” Berthier beforehand instructed GeekWire.
The trail to FDA authorization may additionally be eased by the expansion of different firms within the subject. Different startups growing units for blood self-collection embrace Babson Diagnostics, which landed $31 million final June, and Harbinger Well being.
Tasso will use the brand new funds to extend manufacturing and operations and develop its well being testing companies.
The brand new financing spherical was led by RA Capital Administration, with participation from current traders Foresite Capital, Hambrecht Ducera Development Ventures, J2V, Cedars-Sinai, and Merck GHIF. New traders included the D.E. Shaw group, Senvest, InCube, and SVB Innovation Fund.